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Abstract
A variety of N v-monosubstituted L-arginine analogs are established inhibitors of nitric oxide synthase; in all cases, initial
binding is competitive with the substrate L-arginine. The efficacy of such compounds in vivo will depend on their transport
into the relevant nitric oxide synthase-containing cells; in fact, inhibition may actually be augmented if cellular uptake of
L-arginine is also blocked by the analogs. Because vascular endothelial cells synthesize vasoactive nitric oxide under both
physiological and pathophysiological conditions, we have performed inhibition analyses with novel arginine analogs to
determine the substrate specificity of the primary L-arginine transport system, Naq-independent System yq, present in
porcine pulmonary artery endothelial cells. As reported by others, no Naq-independent System bo,q activity was detectable.
For System yq, Dixon plots suggest competitive inhibition and apparent K values, which ranged between 0.1 and 0.8 mM,i
were estimated for each inhibitor. Some influence of amino acid side chain structure could be detected, but in general, the
data establish that this transport system accepts a broad range of arginine derivatives. Loading the cells with individual
arginine analogs resulted in trans-stimulation of arginine uptake suggesting that they serve as substrates of System yq as
well as inhibitors. These results indicate that plasma membrane transport is unlikely to be a limiting factor in drug
development for nitric oxide synthase inhibitors.
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Abbreviations: CAT, cationic amino acid transporter; HA, homoarginine; NAA, N v-amino-L-arginine; NAHA, N v-amino-L-homo-
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1. Introduction
 .Nitric oxide NO , originally identified as endothe-
 . w xlium-derived relaxing factor EDRF 1 , is synthe-
sized from a guanidino nitrogen of L-arginine by
 .nitric oxide synthase NOS , a NADPH- and O -de-2
w xpendent enzyme 2 . Three isoforms of NOS have
w x 2qbeen identified 2–4 . A Ca rcalmodulin-dependent
constitutive NOS within vascular endothelial cells
 .  .eNOS is activated by blood flow i.e. shear stress
2q  .or by various Ca transport agonists e.g. bradykinin
and produces NO that is an important vasorelaxant in
w xblood pressure homeostasis 3,5–7 . Within some
central and peripheral neurons, a distinct
Ca2qrcalmodulin-dependent, constitutive NOS iso-
 .form nNOS produces NO that serves an incom-
w xpletely characterized role in signal transduction 8 .
Finally, in response to various inflammatory cy-
 .tokines or lipopolysaccharide LPS , many cell types
 .express an inducible NOS isoform iNOS that is not
2q w xregulated by changes in cellular Ca levels 3 .
Vascular smooth muscle and endothelial cells are
among the tissues expressing high levels of iNOS
following exposure to endotoxin or inflammatory
cytokines. In the intact animal, iNOS-mediated over-
production of NO by vascular cells can cause marked
vasorelaxation leading to clinically significant hy-
w xpotensive cardiovascular shock 9 .
Both physiological and pathophysiological NOS-
mediated formation of NO are dependent on an ade-
quate and continuing supply of L-arginine. There are
two potential sources of intracellular L-arginine, de
novo synthesis from other metabolites and exogenous
L-arginine taken up from the bloodstream. The latter
route is particularly important in the pathological
overproduction of NO inpatients with septic shock
w x10 . With regard to exogenous L-arginine uptake,
there are four known L-arginine plasma membrane
transport systems. System yq is a sodium-indepen-
dent system encoded by the CAT1 gene family
w x q11,12 . System y transports only cationic amino
acids in the absence of Naq, but at relatively high
 .concentrations mM certain neutral amino acids can
q w xserve as inhibitors in the presence of Na 13,14 .
Systems Bo,q, bo,q, and yqL are activities that trans-
port both cationic and neutral amino acids at physio-
w xlogic concentrations 15–17 . The relative expression
of these four systems varies widely among different
w xtissues and cell types 18 , but porcine pulmonary
artery endothelial cells have been reported to express
System yq as a primary route for arginine transport
w x19 .
There is considerable interest in the selective inhi-
bition of NOS isoforms, particularly iNOS, in septic
w x w xshock 9,10 and inflammatory conditions 20,21 .
Although several L-arginine analogs such as N v-
 . vnitro-L-arginine methyl ester L-NAME and N -
 .methyl-L-arginine L-NMA have been proposed as
clinically useful NOS inhibitors, these derivatives
w xinhibit all NOS isoforms with little selectivity 2,21 .
We considered that the utility of L-arginine analogs
as NOS inhibitors in vivo is likely to depend on the
substrate specificity and uptake rates of the corre-
sponding transport systems present in the target cell.
 .One of our laboratories OWG has synthesized a
number of potentially useful arginine analogs that are
potent inhibitors of the constitutive and inducible
w xforms of NOS; some are moderately selective 22 .
Therefore, the ability of these analogs to competi-
tively inhibit L-arginine transport by System yq was
examined in porcine pulmonary artery endothelial
 .PPAE cells in primary culture. As mentioned, Sys-
tem yq is a primary transporter of cationic amino
acids in these cells, and its Naq-independent mecha-
nism will permit bi-directional plasma membrane
transport of an arginine analog, if it is an acceptable
substrate. Conversely, if the analog serves as an
inhibitor of System yq, even one that has little or no
translocation, it may block arginine availability for
NO synthesis by the inducible form of the enzyme.
The inhibition analyses reported here revealed that
the endothelial cell System yq activity is strongly
inhibited by a broad range of arginine analogs which
also serve as substrates. These results indicate that a
wide spectrum of arginine analogs may limit L-
arginine uptake significantly, and possibly, also de-
plete intracellular arginine stores by trans-stimula-
tion. The data also demonstrate that transport across
the plasma membrane is unlikely to be a limitation
with regard to development of NOS inhibitors.
2. Materials and methods
2.1. Synthesis of arginine analogs
Arginine analogs and N v-monoalkyl arginine
analogs were prepared from L-ornithine or RS-g-
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methyl-DL-ornithine by the general method of Corbin
w x 2qand Reporter 22 . Briefly, the Cu -complex of or-
nithine or substituted ornithine was reacted under
alkaline conditions with the appropriate S-methyl
th iopseudouron ium iod ide i.e ., R -N H -
 . q yC SCH NH I , where R5H for arginine and g-3 2
methyl-arginine derivatives, and R5CH -, C H - and3 2 7
C H - for N v-methyl, N v-ethyl, N v-propyl, and4 9
v . 2qN -butyl derivatives . After removing Cu with
Chelex resin, the resulting product was separated
from unreacted ornithine or substituted ornithine by
w xcrystallization as the flavianic acid salt 23,24 or by
chromatography on Dowex 50 resin E.B. Campbell
.and O.W. Griffith, unpublished data . Homoarginine
analogs were prepared similarly using L-lysine in
place of L-ornithine. N v-Amino-L-arginine was pre-
pared from N v-nitro-L-arginine as described previ-
w x vously 25,26 . N -Amino-L-homoarginine was pre-
pared from L-lysine and S-methyl thiosemicarbazide,
essentially as described for the N v-alkyl derivatives.
Similarly, N v-methylamino, L-arginine, N v-amino-
N v
X
-methyl-L-arginine, and N v-amino, N v-methyl-
L-arginine were prepared from appropriate substituted
S-methyl thiosemicarbazides and L-ornithine. Nd-im-
 .inoethyl-L-ornithine L-NIO and its higher homologs
were prepared by reaction of the appropriate O-methyl
w ximidate with L-ornithine as described 27 ; imidates
were prepared by treating alkylnitriles with methano-
lic HCl. N v-Iminoethyl-L-lysines were prepared simi-
larly from L-lysine.
All compounds were )95% pure by HPLC and
gave the expected NMR andror elemental analyses.
Structures of the analogs and the abbreviations used
throughout this report are given in Fig. 1. Note that
all analogs contain a strongly basic side chain and
therefore are cationic at pH 7.4.
2.2. Endothelial cell isolation and culture
 .Porcine pulmonary artery endothelial PPAE cells
were obtained from the main pulmonary artery of 6-
to 7-month-old pigs and placed in primary culture as
w xdescribed previously 28 . The primary cultures were
grown in 60-mm diameter plastic culture dishes pre-
treated with fibronectin Sigma Chemical Co., St.
.Louis, MO in Minimum Essential Medium alpha
 .  .MEM-alpha Gibco , 10% fetal bovine serum, and
antimicrobials 100 Urml penicillin and 100 mgrml
.streptomycin . The cultures were grown in a humidi-
fied atmosphere of 5% CO r95% air at 378C. For2
transport assays, the cells were transferred to fi-
bronectin-coated 24-well trays and maintained for 48
h in RPMI-1640 medium supplemented with 2 mM
 .L-glutamine Gibco , 4% fetal bovine serum, and
antimicrobials at 378C.
2.3. Transport measurements
Amino acid transport of radiolabelled L-arginine
w xwas measured by a modification 29 of the method
w xoriginally described by Gazzola et al. 30 . The cells
were washed twice for 15 min each with 2 ml of
Naq-free, choline-containing Krebs–Ringer phos-
 .phate choline KRP buffer at pH 7.4 and 378C.
These incubations remove residual culture medium
and minimize possible trans-effects by allowing par-
tial depletion of the intracellular amino acid pool.
 .The uptake buffers 0.25 ml per well were prepared
from choline KRP buffer containing the indicated
w3 x  .concentrations of L- H arginine Amersham Corp.
and, where noted, unlabeled L-arginine analogs.
Transport assays were initiated by addition of uptake
buffer to the cells at 378C, and 30 s later transport
was stopped by washing the cells four times with
 .ice-cold choline KRP buffer 2 mlrwell . The cells
were allowed to dry, then the cellular protein was
w xprecipitated with trichloroacetic acid 29 . The result-
ing soluble extract was removed for determination of
radioactivity by scintillation counting and the protein
content of each well was determined by a modified
w xLowry method 29 . Data were calculated with soft-
ware that incorporated standard statistical analyses,
and the results are reported as pmol L-arginine trans-
ported per mg protein per unit time, or as percent of
control uptake. All experiments represent the average
of at least four assays, and each experiment was
repeated with several different preparations of en-
dothelial cells to ensure reproducibility.
3. Results
3.1. Inhibition of NOS isoforms by arginine analogs
Previous studies have elucidated the major struc-
tural constraints of arginine analog binding to NOS
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Fig. 1. Structures of arginine analogs used a transport inhibitors. Stereochemically pure derivatives were prepared as described in the text.
w x2 . Briefly, derivatives of L-arginine and L-homo-
arginine are bound with high affinity K or K -50m i
.mM if they include an a-amino and a-carboxyl
group, and are not substituted on both guanidino
nitrogens. If they are monosubstituted on a guanidino
nitrogen, the N v-substituent can be no larger than
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w xn-propyl 31 . Binding remains strong if one guani-
dino -NH is replaced by small n-alkyl groups L-2
. w xNIEO and its homologs 32 ; K. Narayanan and
.O.W. Griffith, unpublished data . Substitution of one
guanidino nitrogen with an amino group L-NAA and
.related compounds results in a potent inhibitor of all
w xNOS isoforms 24,26,33 , whereas substitution with
both an amino and a methyl group yields compounds
w xwith some selectivity of inhibition 22 . Methyl sub-
stitution onto the L-ornithine backbone of arginine
analogs is tolerated to different degrees by nNOS,
eNOS, and iNOS; replacement of g-H by a g-CH3
group increases eNOS inhibition relative to nNOS
w xand iNOS inhibition 34 . Use of these analogs to
block NO formation in vivo requires that they are
 .either: 1 effectively translocated by plasma mem-
brane transporters and subsequently directly inhibit
 .NOS, or 2 inhibit transport with or without translo-
cation, and serve to limit arginine availability to the
cell.
[3 ]3.2. Transport of L- H arginine in porcine pul-
monary artery endothelial cells
Our interest was to characterize the analog inhibi-
tion of Naq-independent System yq transport be-
cause this transporter can function in a bi-directional
mode and permit equilibration of the substrate across
the plasma membrane. The data shown in Fig. 2
confirm that PPAE cells express little or no leucine-
inhibitable Naq-independent L-arginine transport by
o,q w xSystem b 19 . However, as a precaution in all
remaining experiments, System yq activity was as-
sayed as the saturable sodium-independent uptake of
w3 x50 mM L- H arginine in the presence of 10 mM
L-leucine in order to absolutely exclude uptake by
System bo,q.
3.3. L-Arginine kinetics for System yq
Prior to determining the K values for analogi
inhibition, a kinetic analysis of System yq-mediated
w3 xtransport of L- H arginine by PPAE cells was per-
formed at concentrations from 0.075 to 20 mM. A
double-reciprocal plot of these data, after subtraction
of the nonsaturable transport component, is presented
in Fig. 3. Best-fit analysis for either one or two
components indicate the presence of a single Naq-in-
w3 xFig. 2. Analysis of the transport of 50 mM L- H arginine by
porcine pulmonary artery cells. The uptake of 50 mM L-
w3 xH arginine was assayed for 30 s at 378C. The difference
between the uptake in the presence of sodium and choline
represents the Naq-dependent System Bo,q activity. No differ-
ence between the uptake in the presence of choline and choline
plus 10 mM L-leucine, representing Naq-independent System
bo,q activity, was observed. The difference between the uptake in
choline plus 10 mM L-leucine and in choline plus 10 mM
L-arginine was taken as the Naq-independent System yq activity.
The data presented are the averages of four determinations"
standard deviations.
dependent system confirming the earlier inhibition
w x .analyses 19 , Fig. 2 . The apparent K value wasm
0.39 mM and the observed maximal velocity was
 .y1 y15500 pmol mg protein 30 s .
Fig. 3. Kinetic analysis of Naq-independent L-arginine uptake.
Porcine pulmonary artery endothelial cells were assayed for
Naq-independent L-arginine uptake between the concentrations of
0.075 and 20 mM. The transport assays were performed for 30 s
at 378C. The nonsaturable component was subtracted prior to
calculation of the apparent kinetic constants.
( )K.K. McDonald et al.rBiochimica et Biophysica Acta 1324 1997 133–141138
3.4. Determination of the K ˝alues for the L-argininei
analogs
The transport rate of 0.025, 0.05, or 0.20 mM
w3 xL- H arginine was measured in the presence of vary-
ing concentrations of selected arginine analogs. As
representative examples of a strong, moderate, or
weak inhibitor of System yq activity, Dixon plots
w x  . v35 for L-homoarginine HA , N -amino-L-arginine
 . d  .L-NAA , and N -iminoethyl-L-ornithine L-NIEO
are shown in Fig. 4. Similar graphic analysis was
performed for each of the inhibitors. A summary of
the estimated K values obtained for the argininei
analogs studied is provided in Table 1. The K i
values varied between 0.15 and 0.78 mM, not too
dissimilar from the K value of 0.39 mM for L-m
arginine itself. Higher homologs of L-arginine, ho-
 . vmoarginine HA , N -amino-L-homoarginine
 . v  .NAHA , and N -iminoethyl-L-lysine NIEL , were
the most potent inhibitors of System yq. In contrast,
iminoalkyl analogs of L-arginine NIEO, NIPO, and
.NIBO were the weakest of the inhibitors tested, but
even their K values were less than 0.8 mM. Interest-i
v  .ingly, N -iminobutyl-L-lysine NIBO was not nearly
Table 1
K Values for inhibition of Naq-independent system yq trans-i
port by arginine analogs
 .Inhibitors Apparent K mMi
NAA 0.14
NEA 0.30
NBA 0.30
HA 0.24
NAHA 0.14
NMHA 0.50
NIEO 0.78
NIPO 0.65
NIBO 0.75
1-AMA 0.43
2-AMA 0.44
3-AMA 0.25
MARG 0.49
NIEL 0.15
NIBL 0.70
w3 xUptake of 0.025, 0.05, or 0.20 mM L- H arginine was measured
at inhibitor concentrations over the range of 0–5 mM for each
arginine analog. Assays were performed for 30 s at 378C as
described in Section 2. The apparent K values were estimatedi
by computer analysis of Dixon plots. Fig. 4 shows three represen-
tative examples.
Fig. 4. Representative Dixon plots for three inhibitors of L-
arginine transport by System yq in porcine pulmonary artery
endothelial cells. The Naq-independent transport of L-arginine at
 .  .  .0.025 ‘ , 0.05 v , and 0.2 ’ mM was performed in the
presence of inhibitors over a range of concentrations from 0–5
mM. The uptake was measured for 30 s at 378C. The Naq-inde-
pendent uptake rates were corrected by subtracting the nonsat-
 . vurable component. Homoarginine HA, panel a , N -amino-L-
 . d arginine NAA, panel b , and N -iminoethyl-L-ornithine NIEO,
.panel c were chosen to show the range of K values observed.i
For the remainder of these values see Table 1.
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 .as effective as the shorter ethyl derivative Table 1 .
Among the analogs tested, N v-aminomethyl-L-
 . v v Xarginine 1-AMA , N -amino-N -methyl-L-arginine
 . v v 2-AMA , and N -amino-N -methyl-L-arginine 3-
.AMA were intermediate in strength; the 3-AMA
analog was slightly more effective than its isomers.
3.5. Arginine analogs are System yq substrates
To determine if the arginine analogs tested for
inhibition were also translocated, trans-stimulation of
q w3 xNa -independent L- H arginine uptake was assayed.
PPAE cells were incubated for 1 h in the presence of
5 mM arginine analog prior to measurement of 50
mM arginine uptake for 30 s. The analogs selected
 .NAA, NIEO, 1-AMA, and 3-AMA were chosen to
represent a spectrum of K values obtained, rangingi
from 0.14 mM for NAA to 0.78 mM for NIEO.
Trans-stimulation by HA has been reported by others
w xfor a number of different cell types 14 . As shown in
Table 2, each of the four analogs tested caused an
increase in arginine transport consistent with the in-
terpretation that the analogs were themselves sub-
strates. Translocation of these analogs demonstrates
that they will have the potential to decrease NO
production by three mechanisms, indirectly by block-
ing arginine uptake across the plasma membrane,
depletion of intracellular arginine by trans-stimula-
tion, and directly at the NOS enzymes.
Table 2
Trans-stimulation of arginine uptake by individual analogs
Analog Arginine uptake Percent of control
None 152"10 100
NAA 337"10 222
NEIO 258" 7 170
1-AMA 265"15 174
3-AMA 272"31 179
PPAE cells were incubated in Naq-containing Krebs–Ringer
bicarbonate buffer with or without 5 mM of the indicated argi-
nine analog for 1 h at 378C. Following two rapid rinses in
q w3 xNa -free choline KRP, the uptake of 50 mM L- H arginine was
measured for 30 s at 378C as described in Section 2. The results
are the averages"S.D. of at least three assays, and the entire
experiment was performed with two sets of cells to ensure
qualitative reproducibility.
4. Discussion
The present data demonstrate that System yq me-
diates Naq-independent arginine transport into porcine
pulmonary artery endothelial cells with an apparent
K for L-arginine transport of 390 mM, a valuem
w xcomparable to those reported by others 14,19,37–40 .
w xSchmidt et al. 37 reported biphasic kinetics for
L-arginine uptake by PPAE cells and concluded there
were two transport systems with apparent K valuesm
of 6 and 600 mM. Our kinetic analysis used a
substrate concentration range starting at 75 mM and
thus, would not have identified an activity with a Km
of less than 10 mM. Because the kinetic analysis of
w x qSchmidt et al. 37 was performed in Na -containing
medium only, no assignment to System yq can be
made with certainty. Interestingly, they reported that
leucine was not an effective inhibitor of either com-
 .ponent and lysine inhibited K s200 mM only onei
of the activities.
With regard to arginine analogs that are known to
serve as NOS inhibitors, several groups have demon-
v  .strated that N -methyl-L-arginine L-NMA competes
with L-arginine for transport, but the NOS-inhibitory
v  .nitro derivatives, N -nitro-L-arginine L-NNA and
v  .N -nitro-L-arginine methyl ester L-NAME , do not
w x36,37,41–43 . The nitro derivatives appear to be
transported by System L, an activity that mediates the
Naq-independent uptake of neutral, not cationic,
amino acids. From the present studies it is clear that
derivatives that retain a cationic guanidinium or ami-
dine group serve as competitive inhibitors for System
yq. Initial observations for inhibition of arginine
transport by these analogs were confirmed by Dixon
plots used to determine K values for inhibition ofi
Naq-independent System yq. The K values rangedi
from 0.14 to 0.78 mM, a factor of two above and
below the K for L-arginine.m
The present findings elucidate previous observa-
tions regarding inhibition of NOS isoforms by these
analogs and now permit a more detailed interpreta-
w xtion. For example, Rouhani et al. 22 reported that
v v
X  .N -amino-N -methyl-L-arginine 3-AMA is a weak
inhibitor of the acetylcholine-induced relaxation of
rat aortic rings, whereas N v-aminomethyl-L-arginine
 . v v 1-AMA and N -amino-N -methyl-L-arginine 2-
.AMA are measurably better inhibitors. On the other
hand, all three analogs are essentially equivalent in
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their ability to inhibit isolated mouse nNOS. Al-
though one interpretation of those results was that
eNOS and nNOS differed in their recognition of
these arginine analogs, it also was possible that 3-
AMA was simply not transported as effectively as
either 1-AMA or 2-AMA. In fact, as shown here, the
K value for 3-AMA inhibition of System yq wasi
less than those for either 1-AMA or 2-AMA, and its
ability to cause trans-stimulation of arginine trans-
port was as effective as 1-AMA. Therefore, the poor
inhibition of aortic ring relaxation by 3-AMA is more
likely to reflect its binding affinity to eNOS itself.
Overall, our transport inhibition studies character-
ize System yq as having a broad specificity. The data
show that structural modifications of the arginine side
chain already known to be useful in designing par-
tially selective NOS inhibitors are acceptable in-
hibitors and substrates of the transporter. Our data
also provide new insight into the structural con-
straints on substrates of System yq. Like all NOS
isoforms, System yq accepts both L-arginine and
L-homoarginine analogs, tolerates replacement of a
guanidinium -NH by -CH or higher alkyl groups,2 3
accepts N v-amino and alkyl substituents, and permits
g-methyl substitution of the L-ornithine sidechain. In
fact, the data suggest that System yq has a broader
specificity than any of the NOS isoforms. For exam-
ple, N v-butyl-L-arginine is recognized by System yq,
w xbut is a poor inhibitor of all NOS isoforms 31 ; K.
.Narayanan and O.W. Griffith, unpublished data .
Given the apparently ubiquitous distribution of Sys-
tem yq activity in mammalian cells, this important
result indicates that the ability of arginine analogs to
serve as NOS inhibitors is unlikely to be limited by
plasma membrane transport.
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